Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

Pharmacology & Therapeutics
Martin C MichelYong Huo


We have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas those of other ARBs have been included systematically but without intention of completeness. ARBs as a class lower blood pressure in established hypertension and prevent hypertension development in all applicable animal models except those with a markedly suppressed renin-angiotensin system; blood pressure lowering even persists for a considerable time after discontinuation of treatment. This translates into a reduced mortality, particularly in models exhibiting marked hypertension. The retrieved data on vascular, cardiac and renal function and morphology as well as on glucose and lipid metabolism are discussed to address three main questions: 1. Can ARB effects on blood vessels, heart, kidney and metabolic function be explained by blood pressure lowering alone or are they additionally directly related to blockade of the renin-angiotensin system? 2. Are they shared by other inhibitors of the renin-angiote...Continue Reading


Nov 1, 1992·The Journal of Clinical Investigation·M ViswanathanJ M Saavedra
Sep 30, 1992·Biochemical and Biophysical Research Communications·T KatsuyaT Ogihara
Jul 15, 1992·Biochemical and Biophysical Research Communications·C A MauzyF Z Chung
May 14, 1992·European Journal of Pharmacology·K MizunoS Fukuchi
Dec 1, 1992·Circulation Research·L A SechiM Schambelan
Sep 1, 1992·The Journal of Clinical Investigation·R A LafayetteT W Meyer
Jan 15, 1992·Biochemical and Biophysical Research Communications·R D FarhyA G Scicli
Jan 1, 1992·European Journal of Clinical Pharmacology·M NakashimaM Kanamaru
Jun 1, 1992·Hypertension·M J DePasqualeM L Mangiapane
Jun 11, 1992·Naunyn-Schmiedeberg's Archives of Pharmacology·D P BrooksM Gellai
Dec 1, 1991·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·B JoverA Mimran
Oct 1, 1991·Hypertension·W OsterriederH R Baumgartner
Dec 1, 1991·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·W LinzB A Schölkens
Jul 1, 1991·Hypertension·T NabikaY Yamori
Jun 1, 1990·Trends in Pharmacological Sciences·H A Struyker BoudierJ G De Mey
Nov 15, 1990·Biochemical and Biophysical Research Communications·A T ChiuP B Timmermans

❮ Previous
Next ❯


Aug 19, 2016·Frontiers in Pharmacology·Georgios GeorgiopoulosDimitrios Tousoulis
Sep 11, 2016·Naunyn-Schmiedeberg's Archives of Pharmacology·Amal M MahfozAfaf A Shoka
Feb 23, 2018·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Sudeep P PushpakomMunir Pirmohamed
Apr 11, 2018·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Luciana M A BorémSergio H S Santos
Jul 5, 2018·Journal of Cellular and Molecular Medicine·Seth J CoreyRegina M Day
Jul 27, 2017·Journal of the American Heart Association·Tao XuYangmei Chen
Jun 20, 2017·Pharmacological Reviews·Yuri K Peterson, Louis M Luttrell
Jan 13, 2018·Molecular Pharmacology·Martin C Michel, Steven J Charlton
Jul 12, 2017·Cell Discovery·Qiang LiuChengyu Jiang
Aug 7, 2019·Plastic and Reconstructive Surgery·Amanda MurphyMichael Bezuhly
Dec 29, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Liyan BaiMyung Ho Jeong
Mar 19, 2021·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Gianna HuberWalter Raasch
Jun 12, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Laura BeckmannWalter Raasch
Jul 3, 2021·Pharmaceuticals·Mohamed M El-KadyMaha Saber-Ayad
Jul 10, 2021·Experimental Cell Research·Yuting YangJuxiang Li
Jun 5, 2017·Advanced Drug Delivery Reviews·Stefania CannitoMaurizio Parola

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.


Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.